{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:19:02Z","timestamp":1788200342728,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01479-x","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T22:43:48Z","timestamp":1774651428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5538-4943","authenticated-orcid":false,"given":"Alexandre","family":"Bazinet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2745","authenticated-orcid":false,"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-1613","authenticated-orcid":false,"given":"Kelly","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4533-5176","authenticated-orcid":false,"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6017-2264","authenticated-orcid":false,"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Bouligny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5959-397X","authenticated-orcid":false,"given":"Mahesh","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-3362","authenticated-orcid":false,"given":"Wei Ying","family":"Jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Kugler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-6453","authenticated-orcid":false,"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Urrutia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-2748","authenticated-orcid":false,"given":"Georgina","family":"Gener-Ricos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Braish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Briski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"Rodriguez-Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2498-8573","authenticated-orcid":false,"given":"Amin","family":"Alousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L.","family":"Ramdial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"1479_CR1","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","volume":"133","author":"S Ogawa","year":"2019","unstructured":"Ogawa S. Genetics of MDS. Blood. 2019;133:1049\u201359.","journal-title":"Blood"},{"key":"1479_CR2","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"1479_CR3","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"1479_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","volume":"104","author":"CS Cutler","year":"2004","unstructured":"Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579\u201385.","journal-title":"Blood"},{"key":"1479_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.bbmt.2007.11.012","volume":"14","author":"GG Laport","year":"2008","unstructured":"Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transpl. 2008;14:246\u201355.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1479_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","volume":"28","author":"Z Lim","year":"2010","unstructured":"Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28:405\u201311.","journal-title":"J Clin Oncol"},{"key":"1479_CR7","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1200\/JCO.20.03380","volume":"39","author":"R Nakamura","year":"2021","unstructured":"Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, et al. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol. 2021;39:3328\u201339.","journal-title":"J Clin Oncol"},{"key":"1479_CR8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1479_CR9","first-page":"2679","volume":"130","author":"CY Ok","year":"2017","unstructured":"Ok CY, Singh R, Luthra R, Hatfield D, Floyd K, Loghavi S, et al. Endleukemia Assay v1: Enabling NGS-Based Comprehensive Routine Molecular Profiling of Leukemias in Routine Clinical Care. Blood. 2017;130:2679.","journal-title":"Blood"},{"key":"1479_CR10","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1182\/bloodadvances.2023010850","volume":"7","author":"UR Popat","year":"2023","unstructured":"Popat UR, Pasvolsky O, Bassett R Jr, Mehta RS, Olson A, Chen J, et al. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv. 2023;7:6196\u2013205.","journal-title":"Blood Adv"},{"key":"1479_CR11","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1182\/blood-2021-146655","volume":"138","author":"UR Popat","year":"2021","unstructured":"Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, et al. Optimizing myeloablative fractionated busulfan, fludarabine and thiotepa regimen: results of two parallel cohorts in a phase 2 prospective clinical trial. Blood. 2021;138:1802.","journal-title":"Blood"},{"key":"1479_CR12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJM197504242921706","volume":"292","author":"ED Thomas","year":"1975","unstructured":"Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et al. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975;292:895\u2013902.","journal-title":"N Engl J Med"},{"key":"1479_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401.e1.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1479_CR14","first-page":"2047","volume":"141","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Ades L, Borate U, et al. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023;141:2047\u201361.","journal-title":"Blood"},{"key":"1479_CR15","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1182\/bloodadvances.2024015335","volume":"9","author":"A Baranwal","year":"2025","unstructured":"Baranwal A, Langer KJ, Gannamani V, Rud D, Cibich A, Saygin C, et al. Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025;9:3395\u2013407.","journal-title":"Blood Adv"},{"key":"1479_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017;376:536\u201347.","journal-title":"N Engl J Med"},{"key":"1479_CR17","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","volume":"32","author":"R Bejar","year":"2014","unstructured":"Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32:2691\u20138.","journal-title":"J Clin Oncol"},{"key":"1479_CR18","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1200\/JCO.23.00866","volume":"41","author":"J Versluis","year":"2023","unstructured":"Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, et al. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 study. J Clin Oncol. 2023;41:4497\u2013510.","journal-title":"J Clin Oncol"},{"key":"1479_CR19","first-page":"387.e1","volume":"29","author":"R Newcomb","year":"2023","unstructured":"Newcomb R, Johnson PC, Cronin K, Choe JJ, Holmbeck K, Nabily A, et al. Quality of life, physical functioning, and psychological distress of older adults undergoing hematopoietic stem cell transplantation. Transpl Cell Ther. 2023;29:387.e1\u2013e7.","journal-title":"Transpl Cell Ther"},{"key":"1479_CR20","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood.2020006158","volume":"136","author":"Sallman","year":"2020","unstructured":"Sallman, McLemore DA, Aldrich AL AF, Komrokji RS, McGraw KL, Dhawan A, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020;136:2812\u201323.","journal-title":"Blood"},{"key":"1479_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jgo.2014.04.004","volume":"5","author":"HM Holmes","year":"2014","unstructured":"Holmes HM, Des Bordes JK, Kebriaei P, Yennu S, Champlin RE, Giralt S, et al. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. J Geriatr Oncol. 2014;5:422\u201330.","journal-title":"J Geriatr Oncol"},{"key":"1479_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1182\/asheducation-2016.1.99","volume":"2016","author":"AS Artz","year":"2016","unstructured":"Artz AS. Biologic vs physiologic age in the transplant candidate. Hematol Am Soc Hematol Educ Program. 2016;2016:99\u2013105.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1479_CR23","doi-asserted-by":"publisher","first-page":"2052.","DOI":"10.3390\/jcm13072052","volume":"13","author":"M Potiaumpai","year":"2024","unstructured":"Potiaumpai M, Caru M, Mineishi S, Naik S, Zemel BS, Schmitz KH. IMPROVE-BMT: a pilot randomized controlled trial of prehabilitation exercise for adult hematopoietic stem cell transplant recipients. J Clin Med. 2024;13:2052.","journal-title":"J Clin Med"},{"key":"1479_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223\u201332.","journal-title":"Lancet Oncol"},{"key":"1479_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41591-022-01696-4","volume":"28","author":"I Ganan-Gomez","year":"2022","unstructured":"Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, et al. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022;28:557\u201367.","journal-title":"Nat Med"},{"key":"1479_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/leu.2015.179","volume":"30","author":"S Jilg","year":"2016","unstructured":"Jilg S, Reidel V, Muller-Thomas C, Konig J, Schauwecker J, Hockendorf U, et al. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2016;30:112\u201323.","journal-title":"Leukemia"},{"key":"1479_CR27","unstructured":"Abbvie. AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes [updated June 16, 2025. Available from: https:\/\/news.abbvie.com\/2025-06-16-AbbVie-Provides-Update-on-VERONA-Trial-for-Newly-Diagnosed-Higher-Risk-Myelodysplastic-Syndromes."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01479-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01479-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01479-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:16:52Z","timestamp":1774984612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01479-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01479-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KS: Honoraria: Otsuka, Amgen, Chugai Pharma. Consulting or Advisory Role: Novartis, Pfizer, Takeda. Research Funding: Novartis, Enliven Therapeutics. Travel, Accommodations, Expenses: Otsuka, Amgen. GMB: Research Funding: IFM Therapeutics, Takeda. TK: Honoraria: CURE. Consulting or Advisory Role: Novartis, Jazz Pharmaceuticals, Pfizer, AbbVie\/Genentech, Agios, Daiichi Sankyo\/UCB Japan, Liberum, Sanofi, Servier, Pinot Bio, Sellas Life Sciences, Bristol Myers Squibb\/Celgene. Research Funding: Bristol Myers Squibb, Celgene, Amgen, BiolineRx, Incyte, Genentech\/AbbVie, Pfizer, Jazz Pharmaceuticals, AstraZeneca, Astellas Pharma, Ascentage Pharma, Genfleet Therapeutics, Cyclacel, Pulmotech, cellenkos, Glycomimetics, Astex Pharmaceuticals, Iterion Therapeutics, Delta-Fly Pharma, Regeneron, Sellas Life Sciences, Abcuro, DAAN Biotherapeutics. GB: Consulting or Advisory Role: Argenx, PTC Therapeutics, BiolineRx, BioTheryX, Nkarta, Treadwell Therapeutics, Novartis, Catamaran Bio, Takeda, AbbVie. Research Funding: Incyte, GlaxoSmithKline, Cyclacel, BiolineRx, MedImmune, Lilly, Oncoceutics, Ryvu Therapeutics, Janssen Scientific Affairs, Bristol Myers Squibb, AbbVie, Novartis, AstraZeneca, Mundipharma Research, PTC Therapeutics, BioTheryX, XBiotech, Arvinas, Astex Pharmaceuticals, TCR2 Therapeutics, Nkarta, Nkarta, Treadwell Therapeutics, Cellestia Biotech. CD: Honoraria: AbbVie, GlaxoSmithKline, Servier, Genentech\/AbbVie, Astellas Pharma, Bristol Myers Squibb Foundation, Schrodinger, Daiichi Sankyo\/Astra Zeneca, Ellipses Pharma. Consulting or Advisory Role: AbbVie, AstraZeneca, Genmab, Molecular Partners, Servier, Schrodinger, Rigel, Ryvu Therapeutics. Research Funding: AbbVie, Cleave Therapeutics, Foghorn Therapeutics, Immune-Onc Therapeutics, Jazz Pharmaceuticals, Servier, Loxo\/Lilly, Astex Pharmaceuticals, Bristol Myers Squibb\/Celgene, BeiGene, Remix Therapeutics. NS: Honoraria: Amgen. Consulting or Advisory Role: AstraZeneca, NGM Biopharmaceuticals, Pfizer, Takeda, Novartis, Amgen. Research Funding: Takeda, Astellas Pharma, Stemline Therapeutics. NP: Consulting or Advisory Role: Blueprint Medicines, Pacylex, Immunogen, Bristol Myers Squibb, Clearview Healthcare Partners, Astellas Pharma, CTI BioPharma Corp, AbbVie, Aptitude Health, Aplastic Anemia and MDS International Foundation, CancerNet, CareDx, Celgene, Cimeio Therapeutics, Curio Science, Dava Oncology, EUSA Pharma, Harborside Press, Imedex, Intellisphere, Intellisphere, Magdalen Medical Publishing, Medscape, Menarini Group, Neopharm, Novartis, OncLive, Patient Power, Peerview, Pharmaessentia, Physicans\u2019 Education Resource. Research Funding: US DOD. EJ: Consulting or Advisory Role: Pfizer, Takeda, Amgen, AbbVie, Bristol Myers Squibb, Adaptive Biotechnologies, Genentech, Autolus, Ascentage Pharma, Taiho Pharmaceutical, Novartis, TargetRX, Terns Pharmaceuticals. Research Funding: Pfizer, Adaptive Biotechnologies, Ascentage Pharma Group, AbbVie, Takeda, Johnson & Johnson\/Janssen, Jazz Pharmaceuticals, Terns Pharmaceuticals, Taiho Pharmaceutical, Novartis, Amgen, TGRX. Travel, Accommodations, Expenses: Pfizer, Aptitude Health, Autolus, Nucleus Global, ONVIV, MD Education, HMP Education, Daiichi Sankyo Nordics. ND: Consulting or Advisory Role: Celgene, Agios, Jazz Pharmaceuticals, Pfizer, AbbVie, Astellas Pharma, Daiichi Sankyo, Novartis, Bristol Myers Squibb, Amgen, Immunogen, Genentech, Servier, Syndax, Trillium Therapeutics, Gilead Sciences, Arog, Shattuck Labs, Kite, a Gilead company, Stemline\/Menarini. Research Funding: Bristol Myers Squibb, Pfizer, Immunogen, Genentech, AbbVie, Astellas Pharma, Servier, Daiichi Sankyo, Gilead Sciences, Amgen, Trillium Therapeutics, Hanmi, Trovagene, FATE Therapeutics, Novimmune, Glycomimetics, Kite, a Gilead company. FR: Honoraria: Amgen, Pfizer, Astellas Pharma, Celgene, Agios, AbbVie\/Genentech, AstraZeneca, Bristol Myers Squibb, Takeda, Jazz Pharmaceuticals, Novartis, Syros Pharmaceuticals, Taiho Pharmaceutical, Syndax. Consulting or Advisory Role: Amgen, Astellas Pharma, Celgene, Jazz Pharmaceuticals, Agios, AbbVie\/Genentech, Bristol Myers Squibb, AstraZeneca, Taiho Oncology, Syros Pharmaceuticals, Certara Inc. Research Funding: Bristol Myers Squibb, Amgen, Macrogenics, Xencor, Selvita, Cellerant, Astex Pharmaceuticals, Taiho Oncology, Syros Pharmaceuticals, Prelude Therapeutics, Biomea Fusion, Astellas Pharma. HK: Honoraria: AbbVie, Amgen, Pfizer, Ascentage Pharma Group, Ipsen, KAHR Medical, Novartis, Shenzhen Target Rx, Daiichih-Sankyo, Immunogen. Consulting or Advisory Role: AbbVie. Research Funding: Amgen, Bristol Myers Squibb, Novartis, AbbVie, Immunogen, Jazz Pharmaceuticals, Ascentage Pharma, Daiichi Sankyo\/Lilly. GGM: Honoraria: Curis, Bristol Myers Squibb\/Celgene, Taiho Oncology, Ascentage Pharma, Servier, Keros Therapeutics. Consulting or Advisory Role: Bristol Myers Squibb, Taiho Oncology, Curis, Ascentage Pharma, Servier, Keros Therapeutics. Research Funding: Novartis, AbbVie, Bristol Myers Squibb, Genentech, Curis, Rigel, Taiho Oncology, Stemline Therapeutics, Zentalis, Chordia Therapeutics, Jazz Pharmaceuticals. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. This study was approved by the MD Anderson Institutional Review Board (protocol # 2024-0341). The need for informed consent was waived due to the retrospective, non-interventional nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"48"}}